vs
Leonardo DRS, Inc.（DRS）与通用电气医疗（OPCH）财务数据对比。点击上方公司名可切换其他公司
通用电气医疗的季度营收约是Leonardo DRS, Inc.的1.4倍（$1.4B vs $1.1B），Leonardo DRS, Inc.净利率更高（9.6% vs 3.6%，领先6.0%），通用电气医疗同比增速更快（12.2% vs 8.1%），Leonardo DRS, Inc.自由现金流更多（$376.0M vs $130.2M），过去两年Leonardo DRS, Inc.的营收复合增速更高（24.1% vs 13.0%）
莱昂纳多DRS公司是美国本土国防承包商，前身为DRS技术公司，曾于纽约证券交易所挂牌交易，2008年被莱昂纳多的前身芬梅卡尼卡收购，核心业务为向美国军方提供先进国防技术及配套系统产品。
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、磁共振、女性健康筛查及X线设备）、超声、患者护理解决方案（覆盖远程患者监测、麻醉呼吸护理、心脏病诊断、婴儿护理等）及制药相关业务。
DRS vs OPCH — 直观对比
营收规模更大
OPCH
是对方的1.4倍
$1.1B
营收增速更快
OPCH
高出4.2%
8.1%
净利率更高
DRS
高出6.0%
3.6%
自由现金流更多
DRS
多$245.8M
$130.2M
两年增速更快
DRS
近两年复合增速
13.0%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.4B |
| 净利润 | $102.0M | $51.8M |
| 毛利率 | 25.4% | 19.0% |
| 营业利润率 | 11.9% | 5.9% |
| 净利率 | 9.6% | 3.6% |
| 营收同比 | 8.1% | 12.2% |
| 净利润同比 | 14.6% | -3.8% |
| 每股收益（稀释后） | $0.38 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DRSOPCH
| Q4 25 | $1.1B | — | ||
| Q3 25 | $960.0M | $1.4B | ||
| Q2 25 | $829.0M | $1.4B | ||
| Q1 25 | $799.0M | $1.3B | ||
| Q4 24 | $981.0M | $1.3B | ||
| Q3 24 | $812.0M | $1.3B | ||
| Q2 24 | $753.0M | $1.2B | ||
| Q1 24 | $688.0M | $1.1B |
净利润DRSOPCH
| Q4 25 | $102.0M | — | ||
| Q3 25 | $72.0M | $51.8M | ||
| Q2 25 | $54.0M | $50.5M | ||
| Q1 25 | $50.0M | $46.7M | ||
| Q4 24 | $89.0M | $60.1M | ||
| Q3 24 | $57.0M | $53.9M | ||
| Q2 24 | $38.0M | $53.0M | ||
| Q1 24 | $29.0M | $44.8M |
毛利率DRSOPCH
| Q4 25 | 25.4% | — | ||
| Q3 25 | 23.1% | 19.0% | ||
| Q2 25 | 23.8% | 19.0% | ||
| Q1 25 | 22.7% | 19.7% | ||
| Q4 24 | 24.0% | 21.3% | ||
| Q3 24 | 22.0% | 20.1% | ||
| Q2 24 | 22.4% | 20.3% | ||
| Q1 24 | 22.2% | 20.8% |
营业利润率DRSOPCH
| Q4 25 | 11.9% | — | ||
| Q3 25 | 9.7% | 5.9% | ||
| Q2 25 | 8.4% | 5.8% | ||
| Q1 25 | 7.4% | 5.9% | ||
| Q4 24 | 12.2% | 6.9% | ||
| Q3 24 | 9.2% | 6.7% | ||
| Q2 24 | 7.3% | 6.6% | ||
| Q1 24 | 6.3% | 6.0% |
净利率DRSOPCH
| Q4 25 | 9.6% | — | ||
| Q3 25 | 7.5% | 3.6% | ||
| Q2 25 | 6.5% | 3.6% | ||
| Q1 25 | 6.3% | 3.5% | ||
| Q4 24 | 9.1% | 4.8% | ||
| Q3 24 | 7.0% | 4.2% | ||
| Q2 24 | 5.0% | 4.3% | ||
| Q1 24 | 4.2% | 3.9% |
每股收益（稀释后）DRSOPCH
| Q4 25 | $0.38 | — | ||
| Q3 25 | $0.26 | $0.32 | ||
| Q2 25 | $0.20 | $0.31 | ||
| Q1 25 | $0.19 | $0.28 | ||
| Q4 24 | $0.34 | $0.36 | ||
| Q3 24 | $0.21 | $0.31 | ||
| Q2 24 | $0.14 | $0.30 | ||
| Q1 24 | $0.11 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $647.0M | $309.8M |
| 总债务越低越好 | $321.0M | $1.2B |
| 股东权益账面价值 | $2.7B | $1.4B |
| 总资产 | $4.5B | $3.5B |
| 负债/权益比越低杠杆越低 | 0.12× | 0.86× |
8季度趋势，按日历期对齐
现金及短期投资DRSOPCH
| Q4 25 | $647.0M | — | ||
| Q3 25 | $309.0M | $309.8M | ||
| Q2 25 | $278.0M | $198.8M | ||
| Q1 25 | $380.0M | $171.4M | ||
| Q4 24 | $598.0M | $412.6M | ||
| Q3 24 | $198.0M | $483.0M | ||
| Q2 24 | $149.0M | $376.9M | ||
| Q1 24 | $160.0M | $219.5M |
总债务DRSOPCH
| Q4 25 | $321.0M | — | ||
| Q3 25 | $326.0M | $1.2B | ||
| Q2 25 | $331.0M | $1.1B | ||
| Q1 25 | $335.0M | $1.1B | ||
| Q4 24 | $340.0M | $1.1B | ||
| Q3 24 | $345.0M | $1.1B | ||
| Q2 24 | $351.0M | $1.1B | ||
| Q1 24 | $356.0M | $1.1B |
股东权益DRSOPCH
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.6B | $1.4B | ||
| Q2 25 | $2.6B | $1.4B | ||
| Q1 25 | $2.6B | $1.4B | ||
| Q4 24 | $2.6B | $1.4B | ||
| Q3 24 | $2.5B | $1.4B | ||
| Q2 24 | $2.4B | $1.4B | ||
| Q1 24 | $2.4B | $1.4B |
总资产DRSOPCH
| Q4 25 | $4.5B | — | ||
| Q3 25 | $4.2B | $3.5B | ||
| Q2 25 | $4.1B | $3.4B | ||
| Q1 25 | $4.1B | $3.3B | ||
| Q4 24 | $4.2B | $3.4B | ||
| Q3 24 | $3.9B | $3.4B | ||
| Q2 24 | $3.8B | $3.3B | ||
| Q1 24 | $3.8B | $3.2B |
负债/权益比DRSOPCH
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | 0.86× | ||
| Q2 25 | 0.13× | 0.82× | ||
| Q1 25 | 0.13× | 0.82× | ||
| Q4 24 | 0.13× | 0.79× | ||
| Q3 24 | 0.14× | 0.78× | ||
| Q2 24 | 0.15× | 0.79× | ||
| Q1 24 | 0.15× | 0.74× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $425.0M | $139.4M |
| 自由现金流经营现金流 - 资本支出 | $376.0M | $130.2M |
| 自由现金流率自由现金流/营收 | 35.5% | 9.1% |
| 资本支出强度资本支出/营收 | 4.6% | 0.6% |
| 现金转化率经营现金流/净利润 | 4.17× | 2.69× |
| 过去12个月自由现金流最近4个季度 | $227.0M | $220.7M |
8季度趋势，按日历期对齐
经营现金流DRSOPCH
| Q4 25 | $425.0M | — | ||
| Q3 25 | $107.0M | $139.4M | ||
| Q2 25 | $-28.0M | $90.3M | ||
| Q1 25 | $-138.0M | $-7.2M | ||
| Q4 24 | $443.0M | $36.1M | ||
| Q3 24 | $59.0M | $160.4M | ||
| Q2 24 | $34.0M | $195.7M | ||
| Q1 24 | $-265.0M | $-68.8M |
自由现金流DRSOPCH
| Q4 25 | $376.0M | — | ||
| Q3 25 | $77.0M | $130.2M | ||
| Q2 25 | $-56.0M | $81.2M | ||
| Q1 25 | $-170.0M | $-16.6M | ||
| Q4 24 | $414.0M | $25.8M | ||
| Q3 24 | $47.0M | $150.7M | ||
| Q2 24 | $0 | $185.9M | ||
| Q1 24 | $-275.0M | $-74.6M |
自由现金流率DRSOPCH
| Q4 25 | 35.5% | — | ||
| Q3 25 | 8.0% | 9.1% | ||
| Q2 25 | -6.8% | 5.7% | ||
| Q1 25 | -21.3% | -1.2% | ||
| Q4 24 | 42.2% | 2.0% | ||
| Q3 24 | 5.8% | 11.8% | ||
| Q2 24 | 0.0% | 15.1% | ||
| Q1 24 | -40.0% | -6.5% |
资本支出强度DRSOPCH
| Q4 25 | 4.6% | — | ||
| Q3 25 | 3.1% | 0.6% | ||
| Q2 25 | 3.4% | 0.6% | ||
| Q1 25 | 4.0% | 0.7% | ||
| Q4 24 | 3.0% | 0.8% | ||
| Q3 24 | 1.5% | 0.8% | ||
| Q2 24 | 4.5% | 0.8% | ||
| Q1 24 | 1.5% | 0.5% |
现金转化率DRSOPCH
| Q4 25 | 4.17× | — | ||
| Q3 25 | 1.49× | 2.69× | ||
| Q2 25 | -0.52× | 1.79× | ||
| Q1 25 | -2.76× | -0.15× | ||
| Q4 24 | 4.98× | 0.60× | ||
| Q3 24 | 1.04× | 2.98× | ||
| Q2 24 | 0.89× | 3.69× | ||
| Q1 24 | -9.14× | -1.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DRS
暂无分部数据
OPCH
| Commercial Customer | $1.3B | 87% |
| Government Customer | $172.8M | 12% |
| Patient Customer | $10.1M | 1% |
| Corporate Joint Venture | $1.9M | 0% |
